Two Types of mRNA COVID-19 Vaccines Produced by AIM Vaccine was Approved for Clinical Test in Pakistan

2023-02-15 Source:Aimbio
On February 13, 2023, the candidate mRNA vaccine for COVID-19 virus variant strain produced by AIM Vaccine was officially approved for Phase-I clinical test in Pakistan. On the same day, the candidate mRNA vaccine for COVID-19 prime strain produced by our group was officially approved for Phase-III clinical test for sequential booster shot in Pakistan.